NDA 020033 · Validus Pharms
Lotensin Hct
Benazepril Hydrochloride, Hydrochlorothiazide · Oral · Thiazide Diuretic
Last checked: Nov 19, 2026Latest source record: Aug 20, 2020 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1992
May 19, 1992
Approved uses
1
Original approval plus efficacy supplements
Registered trials
53
7 Phase 3, 1 recruiting
FAERS reports
447
265 serious, 27 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: FETAL TOXICITY When pregnancy is detected, discontinue Benazepril HCl and Hydrochlorothiazide as soon as possible. Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus (see WARNINGS: Fetal Toxicity ) .
What it is approved for
From the label in effect Feb 24, 2026.
INDICATIONS AND USAGE Benazepril HCl and Hydrochlorothiazide is indicated for the treatment of hypertension. This fixed combination drug is not indicated for the initial therapy of hypertension (see DOSAGE AND ADMINISTRATION ) .
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- May 19, 1992 Original approval · Type 4 - New Combination
4 products under this application
- LOTENSIN HCT · BENAZEPRIL HYDROCHLORIDE 20MG; HYDROCHLOROTHIAZIDE 25MG · TABLET, ORAL · Prescription · TE AB
- LOTENSIN HCT · BENAZEPRIL HYDROCHLORIDE 5MG; HYDROCHLOROTHIAZIDE 6.25MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · TABLET, ORAL · Discontinued
- LOTENSIN HCT · BENAZEPRIL HYDROCHLORIDE 20MG; HYDROCHLOROTHIAZIDE 12.5MG · TABLET, ORAL · Prescription · TE AB
- LOTENSIN HCT · BENAZEPRIL HYDROCHLORIDE 10MG; HYDROCHLOROTHIAZIDE 12.5MG · TABLET, ORAL · Prescription · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Benazepril" as an intervention, any sponsor and status, largest first.
- Avoiding Cardiovascular Events Through Combination Therapy in Patients Living With Systolic HypertensionPivotal-lookingTerminated
NovartisNovartis (NVS)
NCT00170950 · 11,506 participants · Start Oct 2003 · Primary completion Jan 2008
Drug: Benazepril/amlodipine 20/5 mg - Dose Level 1 from Day 1 to Month 1; Benazepril/amlodipine 40/5 mg - Dose Level 2 from Month 1 to Month 2 and 4 more · For: Hypertension
Sites: East Hanover, New Jersey; Denmark, Denmark; Finland, Finland · 5 sites in all
- Action to Control Cardiovascular Risk in Diabetes (ACCORD)Pivotal-lookingCompleted
National Heart, Lung, and Blood Institute (NHLBI)NIH
NCT00000620 · 10,251 participants · Start Sep 1999 · Primary completion Jun 2009
Drug: Anti-hyperglycemic Agents; Anti-hypertensive Agents and 1 more · For: Atherosclerosis; Cardiovascular Diseases; Hypercholesterolemia and 4 more
Sites: Minneapolis, Minnesota; New York, New York; Winston-Salem, North Carolina · 7 sites in all
- Standard Medical Management in Secondary Prevention of Ischemic Stroke in ChinaPivotal-lookingCompleted
Peking Union Medical College HospitalAcademic, hospital or other
NCT00664846 · 4,000 participants (planned) · Start Apr 2008 · Primary completion Dec 2010
Drug: Aspirin / Clopidogrel, Atorvastatin / Simvastatin; Asprin / Clopidogrel, Atorvastatin / Simvastatin · For: Stroke
Sites: Beijing, China; Chongqing, China; Guangzhou, China · 46 sites in all
- Coronavirus (COVID-19) ACEi/ARB InvestigationPivotal-lookingSuspended
National University of Ireland, Galway, IrelandAcademic, hospital or other
NCT04330300 · 2,414 participants (planned) · Start Apr 30, 2020 · Primary completion Jul 31, 2021
Drug: Thiazide or Thiazide-like diuretics; Calcium Channel Blockers and 2 more · For: Hypertension; COVID-19
Sites: Galway, Ireland
- A Study Comparing the Response of Patients With Hypertension to Amlodipine or Amlodipine Plus Benazepril.Pivotal-lookingCompleted
NovartisNovartis (NVS)
NCT00171366 · 1,422 participants · Start Jul 2004 · Primary completion Jul 2005
Drug: amlodipine/benazepril · For: Hypertension
Sites: East Hanover, New Jersey
- Preventing Microalbuminuria in Type 2 DiabetesPivotal-lookingCompleted
Mario Negri Institute for Pharmacological ResearchAcademic, hospital or other
NCT00503152 · 612 participants · Start May 2007 · Primary completion Jul 2016
Drug: Benazepril; Valsartan and 1 more · For: Diabetes
Sites: Ponte San Pietro, Italy; Ranica, Italy; Romano di Lombardia, Italy · 9 sites in all
- ACEI/CCB Versus ACEI/DIU Combination Antihypertensive Therapy in Chinese Hypertensive Patients (ACvAD)Pivotal-lookingCompleted
Shanghai Jiao Tong University School of MedicineAcademic, hospital or other
NCT03682692 · 560 participants · Start Jun 1, 2018 · Primary completion Jun 30, 2021
Drug: ACEI/CCB; ACEI/DIU · For: Hypertension
Sites: Shanghai, China
- Study on Children Henoch-Schönlein Purpura Nephritis With TCM Multistep TreatmentPivotal-lookingStatus unknown
Henan University of Traditional Chinese MedicineAcademic, hospital or other
NCT03591471 · 500 participants (planned) · Start Sep 2014 · Primary completion Dec 2018
Drug: Glycosides Of Tripterygium Wilfordii Hook(GTW); Sulfotanshinone Sodium Injection and 6 more · For: Henoch-Schönlein Purpura Nephritis
Sites: Zhengzhou, China · 2 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- dizziness30
- diarrhoea24
- nausea23
- headache21
- hypertension21
- pain19
- fatigue18
- blood glucose increased17
- dyspnoea17
- pain in extremity16
- vomiting16
- arthralgia15
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 10 |
| 2005 | 19 |
| 2006 | 15 |
| 2007 | 11 |
| 2008 | 19 |
| 2009 | 21 |
| 2010 | 19 |
| 2011 | 18 |
| 2012 | 24 |
| 2013 | 16 |
| 2014 | 36 |
| 2015 | 25 |
| 2016 | 35 |
| 2017 | 24 |
| 2018 | 39 |
| 2019 | 32 |
| 2020 | 22 |
| 2021 | 13 |
| 2022 | 4 |
| 2023 | 10 |
| 2024 | 10 |
| 2025 | 12 |
| 2026 | 13 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Lotensin HCT (Benazepril/Hydrochlorothiazide)
2024 spending
$10K
Beneficiaries
n/a
38 claims
Per beneficiary
n/a
$2.45 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $11,642 |
| 2021 | $10,561 |
| 2022 | $8,474 |
| 2023 | $9,783 |
| 2024 | $10,378 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Efficacy of single-pill combination in uncontrolled essential hypertension: A systematic review and network meta-analysis.
Xie M, Tang T, Liang H · Clin Cardiol 2023 · Systematic Review, Network Meta-Analysis
- Angiotensin-converting enzyme inhibitor induced cough compared with placebo, and other antihypertensives: A systematic review, and network meta-analysis.
Hu Y, Liang L, Liu S, et al. · J Clin Hypertens (Greenwich) 2023 · Systematic Review, Network Meta-Analysis
- Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients.
Jamerson K, Weber MA, Bakris GL, et al. · N Engl J Med 2008 · Comparative Study, Multicenter Study
- Effect of azilsartan on myocardial remodeling after acute myocardial infarction.
Wang J, Ding Y, Yao YR, et al. · Eur J Clin Pharmacol 2024 · Randomized Controlled Trial
- Antihypertensive treatment effect of two dual therapies according to sodium sensitivity.
Huang QF, Zhang D, Luo Y, et al. · Hypertens Res 2026 · Randomized Controlled Trial, Multicenter Study
- Aldosterone breakthrough with benazepril in furosemide-activated renin-angiotensin-aldosterone system in normal dogs.
Lantis AC, Ames MK, Atkins CE, et al. · J Vet Pharmacol Ther 2015 · Clinical Trial, Research Support, Non-U.S. Gov't
Sponsor: Validus Pharms
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.